Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from ADC Therapeutics ( (ADCT) ) is now available.
On June 3, 2025, ADC Therapeutics SA held its annual general meeting where all proposals were approved by shareholders. Key decisions included the approval of financial statements for 2024, discharge of board members from liability, and reelection of directors and auditors. Additionally, amendments to increase share capital for employee participation were sanctioned, reflecting the company’s strategic focus on growth and employee engagement.
The most recent analyst rating on (ADCT) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on ADC Therapeutics stock, see the ADCT Stock Forecast page.
Spark’s Take on ADCT Stock
According to Spark, TipRanks’ AI Analyst, ADCT is a Neutral.
ADC Therapeutics faces significant financial and operational challenges, impacting its overall stock score. While promising clinical trial results and a solid cash position provide some optimism, the company’s high leverage, ongoing losses, and valuation concerns weigh heavily on its prospects. The overbought technical indicators further suggest caution.
To see Spark’s full report on ADCT stock, click here.
More about ADC Therapeutics
ADC Therapeutics SA operates in the biotechnology industry, focusing on the development of antibody-drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors.
Average Trading Volume: 497,998
Technical Sentiment Signal: Buy
Current Market Cap: $356.1M
For a thorough assessment of ADCT stock, go to TipRanks’ Stock Analysis page.